Blog

Joanna Shields speaks at the Global Partnership on Artificial Intelligence

At the Global Partnership on Artificial Intelligence (GPAI) summit, Benevolent AI CEO Joanna Shields shared her belief that humanity should be at the heart of AI.

Last week international AI experts across industry, civil society, academia and government from over 60 countries came together virtually for the first plenary of the Global Partnership on Artificial Intelligence (GPAI) in Montreal. At the end of an immensely challenging year, the members reflected on the power AI has to fuel discoveries, empower scientists and shape the world when used responsibly.

Our CEO Joanna Shields, proudly represented the United Kingdom as the newly elected Chair of the Steering Committee and the Multistakeholder Group. She shared the stage with Prime Minister Justin Trudeau and the President of France, Emmanuel Macron, who co-led the effort to establish GPAI through their 2018 and 2019 G7 presidencies. The two world leaders addressed the summit with their vision to guide the responsible development and use of AI globally, with Trudeau describing how ‘we must not forget that positive change doesn’t happen by itself, we have to choose it’.

Joanna opened the final plenary of the day with a speech that echoed these words. She focused on the power human ingenuity and AI has to propel us forward, and ultimately benefit all. She described how AI is at its most powerful when it is the result of a fusion between humanity and technology, as well as the need for purposeful technology which reflects the values of our society.

She drew on her learnings from the first digital revolution and the necessity to ensure that frameworks and standards are embedded in our development of new AI. The purpose of GPAI is to provide these guiding principles because, in her words, ‘AI is a powerful force that we cannot afford to underestimate’.


More Posts

You Might Also Like

Blog
Transforming drug discovery with AI: how we’re building and nurturing the best talent for the job
At BenevolentAI, we are on a mission to bring life-changing medicines to patients, and we are looking for collaborative, mission-driven people to join our tech, drug discovery and business operations teams in London, Cambridge and New York.
Oct 17, 2021
News
BenevolentAI identifies novel target for ulcerative colitis and advances candidate to IND/CTA-enabling studies
BenevolentAI’s AI-Drug Discovery platform uncovered a novel target not previously linked to ulcerative colitis and advanced candidate to preclinical studies.
Oct 14, 2021
Blog
Measuring bias: moving towards more inclusive health research outcomes #stateofai
Having shared our open-source Diversity Analysis Tool last year, we were tasked to investigate and demonstrate the lack of diversity in biomedical data as part of the State of AI Report 2021.
Oct 12, 2021
Blog
Expert-augmented computational drug discovery for rare diseases
Combining scientific expertise, computational tools and our AI-enhanced biomedical knowledge graph to successfully uncover a new drug combination for treating a rare brain cancer in children.
Sep 28, 2021
News
BenevolentAI appoints Dr John Orloff to its Board of Directors
Biopharmaceutical veteran Dr John Orloff joins the BenevolentAI Board as a Non-Executive Director as it scales the development of its leading AI-derived drug pipeline.
Sep 9, 2021
Blog
AI in Drug Discovery
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
Jul 13, 2021